文献速递神经介入DSACT

急性缺血性卒中血管内治疗前对比剂过敏的紧急预处理

Emergent Premedication for Contrast Allergy Prior to Endovascular Treatment of Acute Ischemic Stroke.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-08-06

该单中心回顾性队列分析2012至2019年1521例接受血管内治疗的急性缺血性卒中患者,其中60例(4%)有对比剂过敏记录并接受紧急预处理。从预处理到对比剂中位时间24分钟,有过敏记录患者入院至血管内治疗时间未慢于无过敏者(96 vs 134分钟,P=0.32),无患者发生对比剂反应。作者认为该实用方法对有对比剂过敏记录的患者可能安全。

要点

  • 有对比剂过敏记录的急性缺血性卒中患者,紧急预处理后中位24分钟即可接受对比剂。
  • 有过敏记录患者入院至血管内治疗时间未慢于无过敏者(96 vs 134分钟,P=0.32)。
  • 60例有对比剂过敏记录并接受紧急预处理的患者中,无患者发生对比剂反应。

关键影像表现/征象

  • 60例有对比剂过敏记录的患者中,43例(72%)直接进入血管内治疗,17例首次对比剂暴露为CTA。
  • 有对比剂过敏记录患者从入院至血管内治疗的中位时间为96分钟,无过敏记录患者为134分钟(P=0.32),有过敏记录者未更慢。
  • 60例患者中无患者发生对比剂反应。

诊断标准与关键数值

  • 有对比剂过敏记录患者从预处理至对比剂暴露的中位时间为24分钟(四分位距0-36分钟)。

临床应用与阅片要点

  • 作者认为,对于有对比剂过敏记录的患者,在转运途中或神经血管造影室内进行紧急预处理这一实用方法可能安全。
  • 有对比剂过敏记录并接受紧急预处理的患者,入院至血管内治疗时间未慢于无过敏记录者(96 vs 134分钟,P=0.32)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Management of contrast media allergies may lead to treatment delays in patients with acute ischemic stroke undergoing endovascular therapy. The optimal premedication strategy remains unclear. The aim of this report was to analyze our experience with emergent administration of premedication regimens before endovascular therapy.

MATERIALS AND METHODS: We retrospectively reviewed prospective data for all patients undergoing endovascular therapy from 2012 to 2019 at an academic comprehensive stroke center. Records of patients with documented contrast allergy were reviewed and analyzed. Data collected included stroke risk factors and characteristics, historical contrast reaction details, premedication regimens administered, and signs or symptoms of allergic reaction developing post-endovascular therapy. Hospital arrival time to endovascular therapy was compared with that in those who did not have a history of contrast allergy.

RESULTS: We analyzed 1521 patients undergoing endovascular therapy; 60 (4%) had documented contrast allergies and constituted the study cohort. The median age was 73 years (interquartile range, 66-81 years), and 65% were women. The median time from premedication to contrast was 24 minutes (interquartile range, 0-36 minutes). Forty-three patients (72%) proceeded directly to endovascular therapy; in 17 patients, the first contrast exposure was CTA. Time from hospital arrival to endovascular therapy was not slower for patients with documented allergies (96 versus 134 minutes, P = .32). No patients experienced a contrast media reaction.

CONCLUSIONS: In a single-institution cohort study of 60 consecutive patients with documented contrast allergies undergoing endovascular therapy with emergent premedication en route to (or in) the neuroangiography suite, no patients experienced allergic symptoms. This pragmatic approach may be safe for patients who have documented contrast media allergies.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Tonetti DA, Desai SM, Morrison A, et al. Emergent Premedication for Contrast Allergy Prior to Endovascular Treatment of Acute Ischemic Stroke. AJNR Am J Neuroradiol. 2020. PMID: 32763903. doi:10.3174/ajnr.A6720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。